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Abstract
Background: 5-aminosalicylic acids (5-ASAs) have been integral medications in the maintenance and
induction of remission in inflammatory bowel diseases (IBD) for the past several decades. These patients have
a significantly increased risk for developing colorectal cancer (CRC) when compared to the general
population due to the chronic relapsing and remitting inflammatory process that makes neoplasia more likely.
It has been shown in recent studies that 5-ASAs have the potential to reduce the risk of CRC in patients with
IBD, though the research is not in complete agreement. This review was designed to evaluate the most recent
evidence concerning this topic.
Methods: An exhaustive search of available medical literature in MedLINE-Ovid, Web of Science, CINAHL,
MD Consult, and Google Scholar databases produced a total of six articles that fit the criteria set before the
search. Articles were included if they: 1) assessed CRC prevention using 5-ASA medications in IBD patients,
2) were published during or after 2005, and 3) included odds ratios with 95% confidence intervals or p-values
to measure significance.
Results: A total of six retrospective case-control studies were analyzed with a cumulative total of 723 CRC
cases and 2113 controls. Four studies resulted in a statistically significant (p<0.05 or CI<1) risk reduction in
colorectal cancer for IBD patients while the other two studies demonstrated some risk reduction (23-70%)
with trends toward significance (p=0.11 and p=0.10 respectively) though they did not reach a p-value less
than 0.05.
Conclusion: This systematic review found that the majority of studies do show statistically significant risk
reduction of colorectal cancer rates among patients with IBD. Although not all demonstrated statistical
significance, all had an odds ratio of less than one, which signifies a certain level of risk reduction. The two
studies that did not find statistically significant results both observed the effect of 5-ASA use in control
patients for only one year prior to the date of a matched cancer patient’s diagnosis of CRC, leaving into
question whether the length of exposure may have skewed the cancer preventing ability of the drug.
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Abstract 
 
Background: 5-aminosalicylic acids (5-ASAs) have been integral medications in the 
maintenance and induction of remission in inflammatory bowel diseases (IBD) for the 
past several decades.  These patients have a significantly increased risk for developing 
colorectal cancer (CRC) when compared to the general population due to the chronic 
relapsing and remitting inflammatory process that makes neoplasia more likely.  It has 
been shown in recent studies that 5-ASAs have the potential to reduce the risk of CRC in 
patients with IBD, though the research is not in complete agreement. This review was 
designed to evaluate the most recent evidence concerning this topic. 
Methods:  An exhaustive search of available medical literature in MedLINE-Ovid, Web 
of Science, CINAHL, MD Consult, and Google Scholar databases produced a total of six 
articles that fit the criteria set before the search. Articles were included if they: 1) 
assessed CRC prevention using 5-ASA medications in IBD patients, 2) were published 
during or after 2005, and 3) included odds ratios with 95% confidence intervals or p-
values to measure significance. 
Results: A total of six retrospective case-control studies were analyzed with a cumulative 
total of 723 CRC cases and 2113 controls.  Four studies resulted in a statistically 
significant (p<0.05 or CI<1) risk reduction in colorectal cancer for IBD patients while the 
other two studies demonstrated some risk reduction (23-70%) with trends toward 
significance (p=0.11 and p=0.10 respectively) though they did not reach a p-value less 
than 0.05.   
Conclusion: This systematic review found that the majority of studies do show 
statistically significant risk reduction of colorectal cancer rates among patients with IBD.  
Although not all demonstrated statistical significance, all had an odds ratio of less than 
one, which signifies a certain level of risk reduction.  The two studies that did not find 
statistically significant results both observed the effect of 5-ASA use in control patients 
for only one year prior to the date of a matched cancer patient’s diagnosis of CRC, 
leaving into question whether the length of exposure may have skewed the cancer 
preventing ability of the drug.  
Keywords:  5-ASA, colorectal neoplasms, inflammatory bowel disease, Ulcerative 
Colitis, Crohn’s Disease 
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Chemoprevention of Colorectal Cancer with 5-Aminosalicylic Acids in adult 
patients with Inflammatory Bowel Disease 
 
BACKGROUND 
 
 Colorectal cancer (CRC) rates among patients with inflammatory bowel disease 
(IBD) of the colon are significantly higher than in the general population. One study 
placed patients with ulcerative colitis (UC) at 18% increased risk for CRC after 30 years 
with the disease.1 Although the majority of studies have focused their research primarily 
on ulcerative colitis, the extent of risk involved in patients with Crohn’s disease (CD) of 
the colon appears to be the same according to the most recent studies.2,3    
Seeing as patients with IBD are at an increased risk of morbidity and mortality 
from CRC due to the chronic inflammatory nature of their disease, some with the disease 
are more prone to acquire CRC than others.  Factors that have been shown to increase the 
likelihood of acquiring CRC include: first degree relatives with CRC, primary sclerosing 
cholangitis, age of IBD diagnosis, and extent of disease.4-11  On the other hand, certain 
treatment factors such as compliance with surveillance colonoscopy, use of 5-
aminosalicylic acid medications (5-ASA), folic acid supplementation, regular physician 
follow up, and regular low-dose aspirin consumption have been shown to decrease risk 
for neoplasms of the colon in patients with IBD.12-16 
Since many of the factors that put patients at increased risk of colon cancer are 
non-modifiable, research has focused on remission maintenance and chemoprevention in 
an attempt to improve long-term outcomes for these patients. 5-ASAs are first-line anti-
inflammatory medications used to induce and maintain remission in mild to moderate 
cases of active IBD.  The chemical structure of 5-ASA contains the same bioactive 
compounds found in NSAIDs, including aspirin that are shown to inhibit the COX-2 
pathway of prostaglandin and thromboxane synthesis, which in laboratory studies have 
been demonstrated to induce apoptosis and growth suppression of tumor cells.17,18  
Though 5-ASAs have been shown to have varying degrees of chemopreventative 
potential, not all studies agree with one another, and, in some cases, have been 
inconclusive in the past.11,19 This comes despite a systematic review and meta-analysis of 
this topic by Velayos et al in 2005, which concluded that 5-ASAs reduced CRC risk by 
49% with statistical significance.20 A number of studies included in that review lacked 
statistical significance or contained few patients in their research. The power of studies 
conducted after this systematic review have not been completely analyzed nor 
collectively looked at in a recent systematic review such as this.  
The nature of this issue demands studies be performed in an observational manner 
that is retrospective.  In an ideal study, participants would be watched prospectively for 
several years in a randomized control trial (RCT), however withholding treatment from 
the control group is unethical and therefore impossible. The purpose of this study is to 
examine the studies released in the last five years on CRC risk reduction with 5-ASAs in 
IBD patients, since systematic reviews and meta-analyses are the best way to assess the 
validity of clinical questions such as this one. 
METHODS 
 An exhaustive search of applicable studies was performed using the following 
search engines: MedLINE-Ovid, Web of Science, CINAHL, MD Consult, and Google 
Scholar.  The majority of pertinent articles were produced by Web of Science, which was 
then used to broaden the search by means of viewing all other articles/studies that had 
cited a specific article that was deemed to be relevant.  After the extensive search, each 
article’s reference list was analyzed for titles that seemed to match the clinical question at 
hand, which may have not been found in the original online search.  Some of these 
articles had to be requested through Pacific University’s interlibrary services system, or 
“ILLiad.” 
Inclusion Criteria 
Studies integrated in the review had to include adult IBD patients of either 
ulcerative colitis and/or Crohn’s Disease.  Also, there had to be an intervention of any 5-
ASA that was compared to either IBD patients not on 5-ASA treatment or who took 
varying doses or had taken the medicine for a different duration.  All studies had to 
include an analysis on risk reduction (if any) of colorectal cancer with the 5-ASA 
treatment.  In order to eliminate bias, all patients with IBD (ulcerative colitis and 
Crohn’s Disease of the colon) were included. This was done because Crohn’s Disease 
has been shown to have a similar magnitude of risk of CRC when compared to 
ulcerative colitis.2,3,7,21,22  
Exclusion Criteria 
Articles published before 2005 were excluded in order to evaluate the most up to 
date research. Literature reviews, systematic reviews and meta-analyses were also 
excluded unless used as supplemental evidence to the studies reviewed, such as in the 
introduction and conclusion.  
RESULTS 
 
 A total of six articles were found that matched the inclusion and exclusion criteria 
set (See Table 1).  All studies were conducted as case-controls and all included patients 
older than 18 years of age with a diagnosis of IBD.  Cases were defined as patients with 
IBD (either UC or CD) with a diagnosis of CRC or colorectal dysplasia.  Control patients 
were identified as patients with IBD, with at least some patients given a 5-ASA.  The 
controls were matched to cases based on factors that varied from study to study, but these 
included age, sex, extent of IBD, years of IBD, duration of 5-ASA use, age at CRC 
diagnosis, family history of CRC, and time since last colonoscopy.23-28  
In 2009, Tang et al25 published a case-control observational study that discussed 
the effect of a cumulative dose of mesalamine on 18 CRC case patients and 30 controls.  
Twenty-six control patients had a previous diagnosis of UC while the other four had CD.  
Twenty-five CRC patients had a diagnosis of UC and five had CD.  Cases and controls 
were similar and were matched according to sex, race, IBD type, age at IBD diagnosis, 
and length of IBD diagnosis.  This study also looked at past NSAID, steroid, and 6-
mercaptopurine use, which were found to be similar in both groups.25 
The total cumulative dose of mesalamine (a 5-ASA medication) was defined as 
greater or less than 4,500g compared to no mesalamine use whatsoever. Results of the 
multivariate analysis concluded that a total cumulative dose of ≥4,500g mesalamine 
reduced the risk of CRC by 97.6% and demonstrated statistical significance (OR=0.024; 
95% CI=0.0-0.65; p=0.047) Tang et al was not able to prove that there was a significant 
reduction of CRC based on the average daily dose of mesalamine greater or less than 
1.6g/day (p=0.328).25    
In another study by Terdiman et al,23 the regularity of 5-ASA use in the year prior 
to CRC diagnosis in case patients (defined as the index date) was compared between 
cases and controls for chemoprevention of CRC.  The study included a large population 
with a total of 364 case patients with CRC and a previous IBD diagnosis along with a 
total of 1,172 matched controls. “Regularity” of 5-ASA use was determined by the 
investigators to be the number of filled prescriptions, including: zero, 1-2, 3-4, or ≥5.  
This study found no statistical significance with CRC risk reduction for 5-ASAs as a 
whole (p=0.11), nor for mesalamine (p=0.08) or sulfasalazine (p=0.27).   Although the 
study did not reach statistical significance, the risk of CRC, according to the adjusted 
odds ratios, did appear to decrease as the number of prescriptions for “all 5-ASAs” and 
mesalamine increased.23  
Investigators did not account for past 5-ASA use beyond the year prior to the 
index date due to the retrospective and observational nature of the study. There were 
several other crucial factors that were not accounted for in this study, including family 
history of CRC, IBD duration, extent, and severity, and exposure to non-prescription 
medications.23    
The article written by Siegel et al in27 2006 was the only study in this systematic 
review that exclusively included patients with Crohn’s disease of the colon.  This case-
control investigation took 27 cases of CD with CRC and matched them 1:1 with 27 CD 
controls without CRC, then observed the effect of varying exposures (including 5-ASAs) 
before the CRC diagnosis in the case patient.  More specifically, the study looked at 
regular 5-ASA use more than one year prior to the index date of CRC diagnosis, any use 
of 5-ASA in the past, and current use of 5-ASA at the time of the index date.  The study 
revealed a non-significant trend toward protection for regular use of 5-ASA (OR=0.30; 
95% CI=0.05-1.17; p=0.10), with less significant trends for any 5-ASA use (OR=0.50; 
95% CI=0.11-1.87; p=0.39) and current 5-ASA use (OR=0.33; 95% CI=0.06-1.34; 
p=0.15).27    
Another study that assessed the regular use of 5-ASAs in the year prior to CRC 
diagnosis similar to the article by Siegel et al was a study conducted by van Staa et al24 in 
2005. Among 100 case patients and 600 controls of both CD and UC, patients were 
analyzed according to regular (≥six prescriptions in twelve months before index date) and 
irregular (<six prescriptions in the same twelve months) use of 5-ASA medication. 
Overall, regular 5-ASA use from zero to twelve months was attributed to a 40% risk 
reduction in CRC (AOR=0.60; 95% CI=0.38-0.98). The risk reduction from 12-24 
months was 49% (AOR=0.51; 95% CI=0.26-0.99).  When the use of 5-ASAs was broken 
down into specific drugs (mesalamine vs. sulfasalazine vs. other 5-ASAs), mesalamine 
was found to have the greatest protection against cancer with a 69% risk reduction 
(AOR=0.31; 95% CI=0.11-0.84).24  
Since regular use of 5-ASAs in general and mesalamine in particular established 
95% confidence intervals that were less than one, these findings can be conveyed as 
statistically significant.  Dose effect demonstrated decreased risk in the mesalamine 
group. The trend of increased dose did not decrease the risk involved and lifetime 5-ASA 
use beyond two years before the index date was not measured. Additionally, the extent of 
IBD in cases and controls was not assessed nor was it available to the investigators.24    
Rubin et al28 completed a study in 2006 that found significant risk reduction of 
both CRC and dysplasia in patients with ulcerative colitis.  In the study, 26 cases (8 CRC, 
18 dysplasia) were matched to 96 controls and were followed on average for 9.5-11 
years.  This study measured a patient’s total mesalamine exposure in the same way the 
case-control study by Tang et al25 was performed.  
Confounding factors were eliminated in this study after multiple conditional 
logistic regressions were used to control for potential bias. These factors were family 
history of CRC, age, and duration of UC. Once this model was applied to the univariate 
analysis, a daily dose of ≥1.2g of 5-ASA demonstrated a 72% risk reduction (AOR=0.28; 
95% CI=0.09-0.85; p=0.024). This was be compared to the data on dose effect where 
there was a 16% risk reduction per 1000g increase up to 6025g on total cumulative dose 
(AOR=0.84; 95% CI=0.71-1.00; p=0.056) and a 56% risk reduction with every one gram 
increase per day (AOR=0.44; 95% CI=0.09-0.93; p=0.03).28  
Rubin et al28 also accounted for as many variables as possible given the 
retrospective nature of the study and a cumulative 5-ASA dose exposure was monitored. 
Since this study reached statistical significance on a variety of different dosages of 5-
ASA medications, it was deduced that if the patients were not adherent to their 
medication therapy the results should have been even less powerful than what they would 
have been if all patients were compliant with their treatment regime.28     
 In another article that looked solely at patients with ulcerative colitis, Velayos et 
al26 examined predictive and protective factors associated with colorectal cancer. This 
study had very strict matching standards between cases and controls.  A total of 188 cases 
were matched 1:1 with 188 controls on five criteria: gender, maximal extent of ulcerative 
colitis, duration of UC, date of first visit for UC within three years, and year of UC 
diagnosis within five years. The extent of UC was broken down into area involved, 
including: proctitis; proctosigmoiditis, left-sided colitis, and extensive colitis of more 
than 55cm.  Duration of 5-ASA therapy was surveyed for less than 1 year, 1-5 years, 6-10 
years, and more than 10 years.  Short term (less than 1 year) had no protective effect 
(OR=1.0), while 1-5 years use was the only duration of therapy that had a statistically 
significant protective effect (OR=0.4; 95% CI=0.2-0.9; p<0.05). Long term use of 5-
ASAs beyond five years was associated with a 40% risk reduction, though this was not 
statistically significant. It also showed a protective effect with past NSAID, aspirin, and 
corticosteroid use, which all showed significant results for CRC protection with p-values 
less than 0.05. A multiple variable model with conditional logistic regression was used to 
adjust for confounding factors that increased risk of CRC such as family history of CRC 
and pseudopolyps.26    
In the end, a total of two articles looked specifically at 5-ASA dose and its effect 
on prevention, these were conducted by Rubin et al28 and Tang et al25. Both of these 
studies analyzed the total cumulative medication dose, which allowed them to include 
patients who had changed their prescription dosage of 5-ASA at some point in their 
treatment.  Rubin et al28 went further and examined the effect of a daily dose of 5-ASA in 
grams (+/- 1.2g).   
Among the other four articles that assessed the duration of 5-ASA use, the article 
by Terdiman et al23 based its data on the use of 5-ASAs in the year prior to CRC 
diagnosis in the case patient. The other three articles observed the preventative outcomes 
of medication use during and beyond the year prior to when the CRC was discovered in 
the case patients.24,26,27    
DISCUSSION 
 
 The results from the six articles critically appraised in this review demonstrate 
that the majority of evidence supports the claim that 5-ASA medication use is associated 
with a reduced risk of CRC for IBD patients.  The two studies that did not reach 
statistically significant risk reduction for cancer (defined as a p-value less than 0.05), 
showed trends toward a protective effect in both their odds ratios and p-values.23,27  
Limitations of Study 
 
Some studies produced more applicable results than others.  Three studies only 
looked at treatment at or just beyond one year.23,24,27 One critical variable involved in this 
was the fact that none of these studies were able to account for a cumulative effect of 5-
ASAs beyond that one year, meaning some patients may have had a large range of 
exposure to the medication.  Additionally, dose effect was not incorporated into the data, 
leaving in question whether the two articles that did not reach statistical significance 
might have reached significance had they evaluated dose and further extended the 
duration.23,27   
Two studies based their data off of the number of prescriptions filled during a 
specified length of time.23,24 This also created bias in the sense that compliance with 
taking the medication was not accounted for, along with dosage, and number of pills in 
the prescriptions were not evaluated or accounted for. The fact that this information was 
not available to the investigators does not preclude the fact that it confounded the results.  
Dose effect was also not accounted for in the study by Velayos et al.26  
Despite the fact that the article published by Tang et al25 did show statistically 
significant results, it was limited by the fact that there were few patients involved in the 
study (48 total), not all case patients could be matched to controls so 12 were left out of 
the study, and like all studies included in this review, compliance of actual medication 
consumption was not entirely ensured since they were conducted retrospectively.25   
However, the weaknesses found in this article are not strong enough to discount the data 
since the criteria for information collection and case/control matching was so stringent to 
begin with. 
In order to provide more conclusive results, focusing on dose effect or duration of 
treatment solely, would have led to a more specific statement at the end of this review. 
Furthermore, the retrospective and observational nature of these studies was a limitation 
in itself that unfortunately cannot be surpassed with clinical hypotheses such as these.23-28  
Patients cannot have treatment withheld when there is substantial evidence that the 
treatment reduces morbidity or mortality.   
Recommendations for Future Studies 
 
In order to provide more conclusive results, focusing on dose effect or duration of 
treatment solely, would have led to a more specific statement at the end of this review. 
Furthermore, the retrospective and observational nature of these studies was a limitation 
in itself that unfortunately cannot be surpassed with clinical hypotheses such as these.23-28  
Since mesalamine and other 5-ASAs are integral first-line medications for 
maintenance and active disease remission, denying these in a control group is unethical.  
Future studies should therefore concentrate on the effects of various doses, frequency, 
and durations of treatment with this drug class, preferably prospectively for several (>ten) 
years with large populations.  Furthermore, more patient and laboratory studies should 
observe the relationship between 5-ASAs and dysplasia since this is the initial cellular 
abnormality that ultimately leads to cancer. 
In an ideal study, a large population of CRC case patients would be matched and 
compared to control patients based on specific 5-ASA exposures like dose or duration of 
treatment. Furthermore, this type of study should be repeated by more studies that 
conduct their research in the same way, then collectively analyzed in a systematic review, 
as opposed to making a blanket statement for the drug as a whole. It is clear that more 
studies and reviews need to be conducted in this manner to avoid generalizing for many 
studies that are not exactly similar. 
CONCLUSION 
 
 In conclusion, the most current available research has determined that 5-ASAs 
may have the ability to prevent colorectal cancer in patients with IBD, though dose and 
duration have not yet been specified. Four out of the six studies reviewed ended with 
varying levels of chemoprevention with 5-ASAs with statistical power while the other 
two that focused on less than one year treatment did not, however, showed trends toward 
protection.  The benefits from using 5-ASAs for long-term treatment of IBD far outweigh 
the risks, since they are commonly well tolerated medications with relatively few side 
effects, especially when compared to systemic oral corticosteroids.25   
 The promising findings of this review would seem to have little impact given that 
5-ASAs are used first-line in mild to moderate cases of IBD. However, they do suggest 
that using them as maintenance therapy, and not in remission induction alone, may be a 
preferable option for long-term treatment.  Other prevention strategies like regular 
physician visits, surveillance imaging, and alternative drug treatments such as folic acid 
are both encouraged and proven to be effective.  A combination of all of these strategies 
along with 5-ASA use may ultimately result in a lower risk of CRC for patients with an 
inflammatory bowel disease. 
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Author  
(Year) 
Cases/Controls Disease Medication Intervention (Dose/Usage) 
Length of 
Study 
(years) 
Odds Ratio 
(Confidence 
Interval=95%) 
Risk 
Reduction 
Statistically Significant 
Prevention/Protection 
Tang et al25 
(2009) 18/30 
Crohn’s & Ulcerative 
Colitis 
Mesalamine 
only 
≥4,500g cumulative 
taken 
1970-2005 
(35) 0.024 (0.00-0.65) 98% Yes (p=0.047) 
Terdiman et al23 
(2007) 364/1172 
Crohn’s & Ulcerative 
Colitis 5-ASA 
>5 prescriptions in 1 
yr before CRC† 
2000-2004 
(4) 0.77 (0.54-1.08) 23% No (p=0.11) 
Rubin, et al28 
(2006) 26/96 Ulcerative Colitis 5-ASA >1.2g/day 
1985-2000 
(15) 0.28 (0.09-0.85) 72% Yes (p=0.011) 
Siegel et al27 
(2006) 27/27 Crohn’s 5-ASA 
>1 year use before 
CRC 
1990-2004 
(14) 0.30 (0.05-1.17) 70% No (p=0.10) 
Velayos et al26 
(2006) 188/188 Ulcerative Colitis 5-ASA 1-5 years use 
1976-2003 
(27) 0.60 (0.30-1.21) 40% Yes (p<0.05) 
van Staa, et al24 
(2005) 100/600 
Crohn’s & Ulcerative 
Colitis 5-ASA Use 1 year before CRC 
1987-2001 
(14) 0.60 (0.38-0.96) 40% 
Yes (95% Confidence 
Interval is less than 1) 
 
†Colorectal cancer
Table 1: Statistical Results of Colorectal Cancer Prevention/Protection with 5-ASA use 
 
 
Author/  Title/ 
Journal 
Yr. 
published 
Patients/ 
Population 
Intervention Comparison Outcome(s) Study type Comments 
Terdiman et al23 2007 1536 IBD† 
pts: 364 
CRC‡ cases 
and 1172 
controls 
5-ASA No 5-ASA use 23 % RR§ in 
CRC 
Observational/ 
Case Control 
Did not account for severity or medication dose 
and only 1 year treatment: NO statistical proof 
of decreased risk but trend toward statistical 
significance with p-value 
van Staa et al24 2005 700 IBD pts: 
100 cases 
with CRC 
and 600 
control 
5-ASA No 5-ASA use 40% RR in 
CRC  
Observational/
Case Control 
Second largest study-accounted for disease 
duration; showed decreased risk of CRC 
Tang et al25 2009 1594 IBD 
pts: 18 cases 
30 controls 
<4.5g 
Mesalamine 
and >4.5g 
mesalamine 
No mesalamine, 
<4.5g  
98% RR in 
CRC 
Observational/
Case Control 
Very few limitations: accounted for 
age/sex/race/type of inflammatory bowel 
disease/body mass index/smoking 
history/family history of CRC/etc. Only study to 
associate dose of mesalamine with CRC risk 
reduction. 97.6% risk reduction with 4.5g/day 
of mesalamine p=0.047 
Velayos et al26 2006 376 UC pts: 
188 cases of 
ulcerative 
colitis with 
CRC and 
188 controls 
with CUC 
Varying 
years 
duration of 
5-ASA 
therapy 
(<1y->10y) 
Other anti-
inflammatories/
steroids/folate 
and no 5-ASA 
use 
40% RR in 
CRC 
Observational/
Case Control 
Good study: cases were matched to controls 1:1 
regarding sex/extent of ulcerative 
colitis/duration of ulcerative colitis/first visit at 
Mayo clinic/year of ulcerative colitis diagnosis; 
did not account for dose 
Siegel et al27 
 
2006 54 Crohn’s 
disease pts: 
27 CRC 
cases and 27 
controls 
5-ASA No 5-ASA use, 
any 5-ASA use, 
current 5ASA 
use and regular 
5-ASA use 
70% RR in 
CRC 
Observational/
Case Control 
Revealed non-significant trend toward 
protection, however duration of treatment in 
“regular” users of 5-ASAs was not investigated 
(only specified more than 1 year of use) nor was 
the dose patients were taking. 
Rubin et al28 2006 122 
ulcerative 
colitis pts: 26 
cases with 
CRC and 96 
controls 
5-ASA No 5-ASA use 72% RR in 
CRC 
Observational/
Case Control 
Measured total cumulative mesalamine 
exposure similar to Tang et al.25 Demonstrated 
statistically significant risk reduction of 72% 
p=0.01. 
 
† Inflammatory Bowel Disease 
‡ Colorectal Cancer 
§ Risk Reduction 
Table 2: Summary Matrix of the Literature 
